FDA grants Breakthrough Therapy Designation to zoldonrasib for lung cancer treatment. The drug targets patients with prior standard therapy experience, potentially accelerating development and approval.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
FDA Grants Breakthrough Status to Zoldonrasib in Lung Cancer | CURE
Zoldonrasib Drug Name
FDA Breakthrough Therapy Designation Regulatory Status
Lung Cancer Target Cancer
Revolution Medicines Developer